GLP-1 receptor agonists target cardiometabolic dysfunction in obesity-related heart failure with preserved ejection fraction.
Glucagon-like Peptide-1 Therapy in Obesity-Related Heart Failure with Preserved Ejection Fraction: Mechanisms, Clinical Evidence, and Implications
Abstract
GLP-1 receptor agonists offer significant cardiometabolic benefits, addressing inflammation and metabolic disturbances in obesity-related heart failure with preserved ejection fraction (HFpEF).